Targeting RAS-Driven Cancers

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this live activity for a maximum of 19.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Wednesday, January 23, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via email. Your CME certificate will be sent to you via email after the completion of the activity.


Statement of Educational Need, Target Audience, and Learning Objectives

RAS proteins are proto-oncogenes that are frequently mutated in human cancers, including pancreatic cancer. Typically, RAS functions as an on-off switch to control downstream cellular signaling pathways. Mutations occur when RAS becomes stuck in the "on" position.

There are three RAS genes: HRAS, KRAS, and NRAS. Mutations in KRAS, in particular, are present in 30% of all cancers. The prognosis for many patients with mutations in the RAS gene is poor, increasing the clinical burden. Over the last several years, significant advances have been made in understanding RAS oncogenesis. These advances have grown since the discovery of KRAS; however, it is commonly thought that mutant KRAS is an intractable drug target.

Over the last five years, there has been an invigoration in the field as a result of key therapeutic advances and improvements in available technologies. These advances have led to the discovery of therapeutics directly targeting KRAS, helping KRAS re-emerge as a “druggable” target. 

Substantial gains in the understanding of proximal targeting of KRAS have been made in recent years. Given the prominent role of RAS in human cancers, a comprehensive and in-depth forum for all constituents interested in RAS research is necessary. The need to educate and advance research from basic biology to targeted therapies in RAS continues and grows in intensity. This conference will cover a range of topics from RAS structure and biophysics, to targeting KRAS and KRAS-effector complexes. It will also address systems approaches and models of RAS-driven cancers, and integrate immunotherapy and immunotargets.

The primary focus of this AACR Special Conference will be to discuss both the progress and the many still-unresolved issues that will affect how these discoveries can be leveraged. This conference will bring together academia and industry to assess the opportunities, challenges, and prospects of achieving a therapeutic approach for the ~30% of human cancers that are RAS-mutant.

This activity would be most appropriate for physicians and health care workers who work with patients who have cancers that are or have a high probability of being driven by a RAS mutation, including but not limited to pancreatic cancer, colon cancer, biliary tract cancer, and malignant melanoma.

After participating in this CME activity, physicians should be able to:

1. Evaluate models of KRAS-driven cancer biology in the context of utility/application, such as therapeutic development.
2. Interpret the continued challenges to developing clinical strategies for KRAS-driven cancers.
3. Distinguish between presented therapeutic targets in KRAS biology and the possibility of near-term success in applications.
4. Integrate laboratory and clinical observations.
5. Identify and analyze emergent areas in KRAS biology and areas with a continued need for knowledge/technological expansion.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgment of Financial or Other Support

This activity is supported by Professional Educational Grants and will be disclosed at the activity.

Questions about CME?

Please contact the Office of CME at (215) 440-9300 or